5 unknown, 4 completed, 2 terminated, 1 active not recruiting. 4 Phase 1, 4 Phase 2, 3 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Unknown 2, Active not recruiting 1, Terminated 1 |
| Phase 2 | 4 | Terminated 2, Completed 1, Unknown 1 |
| Not applicable | 3 | Completed 3 |
Follow Invasive Bladder Cancer: new trials by email Literature Review of Invasive Bladder Cancer trials Research Report on Invasive Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nordic Cystectomy Study III - Transfusion Blood transfusion - Bladder Cancer, Invasive Bladder Cancer | Unknown | Turku University Hospital | 1700 | 2020-09-30 | 2020-11-25 | |
| Nordic Cystectomy Study I - Neutrophil-lymphocyte Ratio (NLR) NLR-ratio - Bladder Cancer, Invasive Bladder Cancer | Unknown | Turku University Hospital | 230 | 2020-08-30 | 2020-11-25 | |
| Nordic Cystectomy Study II - Albumin S-Albumin - Bladder Cancer, Invasive Bladder Cancer | Unknown | Turku University Hospital | 1700 | 2020-08-30 | 2020-11-25 | |
| Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE) Atezolizumab, BCG - Invasive Bladder Cancer | Phase 1 | Unknown | Fundacion Oncosur | 40 | 2020-02-03 | 2024-05-21 |
| Testing the Utilization of a Mobile Health App for Patients Undergoing Cystectomy Surgery for Bladder Cancer Mobile Health app tool - Twistle - Invasive Bladder Cancer | Not applicable | Completed | UNC Lineberger Comprehensive Cancer Center | 33 | 2019-03-25 | 2020-06-12 |
| A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study nivolumab 480mg, nivolumab 3mg/kg, ipilimumab 1mg/kg, nivolumab 1mg/kg, ipilimumab 3mg/kg - Urinary Bladder Cancer, Invasive Bladder Cancer | Phase 1 / Phase 2 | Unknown | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 50 | 2019-01-07 | 2022-08-12 |
| A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer Avelumab - Bladder Cancer, Metastatic Bladder Cancer | Phase 1 / Phase 2 | Terminated | Baylor College of Medicine | 1 | 2018-12-14 | 2020-08-24 |
| Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach Durvalumab, Tremelimumab, Radiotherapy - Invasive Bladder Cancer | Phase 2 | Completed | Spanish Oncology Genito-Urinary Group | 32 | 2018-11-19 | 2024-12-05 |
| HIPEC After Radical Cystectomy for High Risk Bladder Cancer HIPEC - Invasive Bladder Cancer | Not applicable | Completed | Weill Medical College of Cornell University | 7 | 2018-04-19 | 2023-08-28 |
| Intravenous Lidocaine for Cystectomy Procedures Cystectomy, Lidocaine, Saline - Invasive Bladder Cancer | Not applicable | Completed | CAMC Health System | 50 | 2016-10-12 | 2022-03-09 |
| Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer Pembrolizumab, Radiotherapy - Invasive Bladder Cancer | Phase 1 | Active not recruiting | Royal Marsden NHS Foundation Trust | 34 | 2016-06-06 | 2026-01-06 |
| Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin Gemcitabine and fractionated cisplatin (combination treatment) - Invasive Bladder Cancer, Bladder Cancer | Phase 2 | Terminated | Brown University | 2 | 2014-07-01 | 2016-08-24 |
| MRI and Bladder Cancer Chemotherapy Invasive Bladder Cancer | Withdrawn | NYU Langone Health | 2013-08-01 | 2014-10-02 |
Urinary Bladder Neoplasms (7) · Neoplasm Metastasis (1) · Non-Muscle Invasive Bladder Neoplasms (1)
Neoplasms (8) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Male Urogenital Diseases (7) · Neoplasms by Site (7) · Urinary Bladder Diseases (7) · Urogenital Diseases (7) · Urogenital Neoplasms (7) · Urologic Diseases (7) · Urologic Neoplasms (7) · Carcinoma (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1) · Neoplastic Processes (1) · Pathologic Processes (1)
Radiotherapy (2) · Blood Transfusion (1) · Capecitabine (1) · Cystectomy (1) · Gemcitabine (1) · Hyperthermic Intraperitoneal Chemotherapy (1) · Ipilimumab (1) · Lidocaine (1) · Mitomycin (1) · Nivolumab (1) · Sodium Chloride (1) · atezolizumab (1) · avelumab (1) · durvalumab (1) · pembrolizumab (1)
Turku University Hospital (3) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Baylor College of Medicine (1) · Brown University (1) · CAMC Health System (1) · Fundacion Oncosur (1) · NYU Langone Health (1) · Royal Marsden NHS Foundation Trust (1) · Spanish Oncology Genito-Urinary Group (1) · UNC Lineberger Comprehensive Cancer Center (1) · Weill Medical College of Cornell University (1)
United States (6) · Finland (3) · Spain (2) · Netherlands (1) · United Kingdom (1)
Adriaan D. Bins, MD PhD (1) · Andrew B Rosenkrantz, MD (1) · Angela B Smith, MD,MS,FACS (1) · Arjun Balar, MD (1) · Daniel Castellano, MD (1) · Douglas S Scherr, MD (1) · Jennifer M. Taylor, MD (1) · Professor Robert Huddart (1) · Samuel G Deem, DO (1)
2019 (1)